The use of cannabidiol in epilepsy: therapeutic and legal advances
DOI:
https://doi.org/10.56294/shp2024138Keywords:
epilepsy, cannabidiol, treatment, legislation, neuroprotectionAbstract
Epilepsy was defined as a chronic neurological condition characterised by spontaneous and repeated epileptic seizures. Its diagnosis was based on criteria established by the International League Against Epilepsy (ILAE), such as the occurrence of multiple unprovoked seizures or the identification of an epileptic syndrome. The classification of epilepsy allowed treatments to be individualised according to the type of seizure, although a significant percentage of patients presented refractory epilepsy, with no adequate response to conventional medication. Over recent decades, interest in new therapies has increased, including cannabidiol (CBD), a non-psychoactive compound from the Cannabis sativa plant. Preclinical and clinical research has demonstrated its anticonvulsant and neuroprotective potential and its role as a modulator of the endocannabinoid system, especially in severe epileptic syndromes such as Lennox-Gastaut and Dravet. CBD acted without directly binding to the classic receptors of the endocannabinoid system, which broadened its therapeutic potential in other conditions, such as anxiety, chronic pain, inflammatory and neurodegenerative diseases. In Argentina, legal progress was made in the medicinal use of cannabis. Law 27.350 and Decree 883/2020 allowed regulated access to CBD, including self-cultivation for therapeutic purposes. In 2022, Law 27.669 promoted the industrial development of medicinal cannabis, with the creation of the ARICCAME agency. Despite this progress, it was still considered essential to continue researching in order to understand the mechanisms of CBD, define its safe doses and evaluate its long-term effectiveness.
References
1. Stafstrom CE, Carmant L. Seizures and epilepsy: an overview for neuroscientists. Cold Spring Harb Perspect Med. 2015 Jun 1;5(6):a022426. doi:10.1101/cshperspect.a022426. PMID: 26033084; PMCID: PMC4448698.
2. Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, Engel J Jr. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005 Apr;46(4):470-2. doi:10.1111/j.0013-9580.2005.66104.x. PMID: 15816939.
3. Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 Apr;58(4):522-30. doi:10.1111/epi.13670. PMID: 28276060.
4. Walker MC, Köhling R. The problems facing epilepsy therapy. Neuropharmacology. 2013 Jun;69:1-2. doi:10.1016/j.neuropharm.2013.02.007. PMID: 23435169.
5. Dorj G. Pharmacotherapy: A Pathophysiologic Approach, 8th Edition. Cent Asian J Med Sci [Internet]. 2017 Nov 25 [cited 2024 Jul 14];3(3):318-9. Available from: https://www.mongoliajol.info/index.php/CAJMS/article/view/2732
6. Patra PH, Barker-Haliski M, White HS, Whalley BJ, Glyn S, Sandhu H, et al. Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models. Epilepsia. 2019 Feb;60(2):303-14. doi:10.1111/epi.14629. PMID: 30588604; PMCID: PMC6378611.
7. Stafstrom CE, Carmant L. Seizures and epilepsy: an overview for neuroscientists. Cold Spring Harb Perspect Med. 2015 Jun 1;5(6):a022426. doi:10.1101/cshperspect.a022426. PMID: 26033084; PMCID: PMC4448698.
8. Campos AC, Fogaça MV, Sonego AB, Guimarães FS. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res. 2016 Oct;112:119-27. doi:10.1016/j.phrs.2016.01.033. PMID: 26845349.
9. Cabral GA, Griffin-Thomas L. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med. 2009 Jan 20;11:e3. doi:10.1017/S1462399409000957. PMID: 19152719; PMCID: PMC2768535.
10. Lazarini-Lopes W, Do Val-da Silva RA, da Silva-Júnior RMP, Leite JP, Garcia-Cairasco N. The anticonvulsant effects of cannabidiol in experimental models of epileptic seizures: From behavior and mechanisms to clinical insights. Neurosci Biobehav Rev. 2020 Apr;111:166-82. doi:10.1016/j.neubiorev.2020.01.014. PMID: 31954723.
11. Kochen S, Villanueva M, Bayarres L, Daza-Restrepo A, Gonzalez Martinez S, Oddo S. Cannabidiol as an adjuvant treatment in adults with drug-resistant focal epilepsy. Epilepsy Behav. 2023 Jul;144:109210. doi:10.1016/j.yebeh.2023.109210. PMID: 37196452.
12. Anwar A, Saleem S, Patel UK, Arumaithurai K, Malik P. Dravet Syndrome: An Overview. Cureus. 2019 Jun 26;11(6):e5006. doi:10.7759/cureus.5006. PMID: 31497436; PMCID: PMC6713249.
13. Connolly MB. Dravet Syndrome: Diagnosis and Long-Term Course. Can J Neurol Sci. 2016;43(S3):S3–8. doi:10.1017/cjn.2016.243.
14. Asadi-Pooya AA. Lennox-Gastaut syndrome: a comprehensive review. Neurol Sci. 2018 Mar;39(3):403-14. doi:10.1007/s10072-017-3188-y. PMID: 29124439.
15. Registro del Programa Cannabis [Internet]. 2024 Apr 15 [cited 2024 Jul 14]. Available from: https://reprocann.msal.gob.ar/auth
16. Silva GD, Del Guerra FB, de Oliveira Lelis M, Pinto LF. Cannabidiol in the Treatment of Epilepsy: A Focused Review of Evidence and Gaps. Front Neurol. 2020 Oct 19;11:531939. doi:10.3389/fneur.2020.531939. PMID: 33192966; PMCID: PMC7604476.
17. Golub V, Reddy DS. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders. Adv Exp Med Biol. 2021;1264:93-110. doi:10.1007/978-3-030-57369-0_7. PMID: 33332006.
18. Golub V, Reddy DS. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders. Adv Exp Med Biol. 2021;1264:93-110. doi:10.1007/978-3-030-57369-0_7. PMID: 33332006.
19. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016 Mar;15(3):270-8. doi:10.1016/S1474-4422(15)00379-8. PMID: 26724101.
20. Lattanzi S, Trinka E, Striano P, Rocchi C, Salvemini S, Silvestrini M, et al. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome. CNS Drugs. 2021 Mar;35(3):265-81. doi:10.1007/s40263-021-00807-y. PMID: 33754312; PMCID: PMC8005394.
21. Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, et al. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):741-53. doi:10.1136/jnnp-2017-317168. PMID: 29511052.
22. Villanueva V, Carreño-Martínez M, Gil Nagel-Rein A, López-González FJ. New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol. Rev Neurol. 2021 Apr 30;72(S01):S1-S10. doi:10.33588/rn.72S01.2021017. PMID: 33908026.
23. Herrera ML, Burneo JG. Síndrome de Lennox Gastaut. Aproximación diagnóstica y avances terapéuticos: Fármacos antiepilépticos, Canabidiol y otras alternativas. Rev Neuropsiquiatr [Internet]. 2018 Jul 5 [cited 2024 Jul 14];81(2):82. Available from: https://revistas.upch.edu.pe/index.php/RNP/article/view/3337
24. Laux LC, Bebin EM, Checketts D, Chez M, Flamini R, Marsh ED, et al. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Epilepsy Res. 2019 Aug;154:13-20. doi:10.1016/j.eplepsyres.2019.03.015. PMID: 31022635.
25. Belle-Isle L, Walsh Z, Callaway R, Lucas P, Capler R, Kay R, et al. Barriers to access for Canadians who use cannabis for therapeutic purposes. Int J Drug Policy. 2014 Jul;25(4):691-9. doi:10.1016/j.drugpo.2014.02.009. PMID: 24947993.
26. Aran A, Cayam-Rand D. Medical Cannabis in Children. Rambam Maimonides Med J. 2020 Jan 30;11(1):e0003. doi:10.5041/RMMJ.10386. PMID: 32017680; PMCID: PMC7000154.
27. Rojas-Jara C, Polanco-Carrasco R, Cisterna A, Hernández V, Miranda F, Moreno A, et al. Uso medicinal de cannabis: una revisión de la evidencia. Ter Psicol. 2019;37(2):166–80.
28. Durkin A. Legalization of marijuana for non-medical use: health, policy, socioeconomic, and nursing implications. J Psychosoc Nurs Ment Health Serv. 2014 Sep;52(9):22-6. doi:10.3928/02793695-20140721-03. PMID: 25082163.
29. Grbic J, Goddard P, Ryder D. Observations of the role of science in the United States medical cannabis state policies: Lessons learnt. Int J Drug Policy. 2017 Apr;42:109-14. doi:10.1016/j.drugpo.2016.12.019. PMID: 28190671.
30. Silvestro S, Mammana S, Cavalli E, Bramanti P, Mazzon E. Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials. Molecules. 2019 Apr 12;24(8):1459. doi:10.3390/molecules24081459. PMID: 31013866; PMCID: PMC6514832.
31. Guiard BP, Di Giovanni G. Central serotonin-2A (5-HT2A) receptor dysfunction in depression and epilepsy: the missing link? Front Pharmacol. 2015 Mar 17;6:46. doi:10.3389/fphar.2015.00046. PMID: 25852551; PMCID: PMC4362472.
Published
Issue
Section
License
Copyright (c) 2024 Vitor Nifoci , Cristian Emanuel Cabrera (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
